Synthetic cytotoxicity: digenic interactions with TEL1/ATM mutations reveal sensitivity to low doses of camptothecin

Area of Science:

• Molecular Biology
• Cancer Research
• Genetics

Background:

• Many tumors exhibit defects in DNA-damage response and genome stability pathways.
• DNA-damaging agents show differential efficacy against cancer cells with impaired DNA repair.
• Exploiting these vulnerabilities offers therapeutic potential.

Purpose of the Study:

• To screen for synthetic cytotoxic interactions with camptothecin and a TEL1 (ATM ortholog) mutation in yeast.
• To identify novel gene targets that sensitize cancer cells to DNA-damaging agents.
• To explore the therapeutic potential of synthetic cytotoxicity.

Main Methods:

• Utilized the Saccharomyces cerevisiae nonessential gene-deletion collection for screening.
• Employed camptothecin, a topoisomerase I inhibitor, as the DNA-damaging agent.
• Focused on synthetic cytotoxic interactions with a null mutation in TEL1.

Main Results:

• Identified and validated 14 synthetic cytotoxic interactions, defining at least five epistasis groups.
• Discovered that telomere defects constitute one class of synthetic cytotoxicity.
• Demonstrated conservation of at least one synthetic cytotoxic interaction in Caenorhabditis elegans.

Conclusions:

• Synthetic cytotoxicity is a viable strategy for enhancing tumor cell sensitivity to DNA-damaging therapeutics.
• This approach can be leveraged to exploit specific genetic defects in cancer cells.
• The findings provide a foundation for developing targeted cancer therapies.